APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Lacosamide

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Lacosamide Market Outlook and Growth Opportunities 2026

Report ID 174006220422 December 2025199 pages

Choose your research edition.

Industry ResearchLacosamide Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Lacosamide Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Lacosamide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lacosamide Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Lacosamide Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Lacosamide market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Lacosamide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lacosamide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lacosamide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Lacosamide market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Lacosamide market include UCB, Teva, Sun Pharma, Mylan, MSN Laboratories, Glenmark, Aurobindo Pharma, Apotex and Amneal Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Lacosamide market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lacosamide and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lacosamide revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Lacosamide market.

Lacosamide Segment by Company

UCB

Teva

Sun Pharma

Mylan

MSN Laboratories

Glenmark

Aurobindo Pharma

Apotex

Amneal Pharmaceuticals

Alembic Pharma

Accord Healthcare

Lacosamide Segment by Type

Intravenous

Oral tablets

Oral solution

Lacosamide Segment by Application

Adults

Pediatric patients

Lacosamide Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Lacosamide status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Lacosamide key companies, revenue, market share, and recent developments.

3. To split the Lacosamide breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Lacosamide market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Lacosamide significant trends, drivers, influence factors in global and regions.

6. To analyze Lacosamide competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lacosamide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lacosamide and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lacosamide.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Lacosamide industry.

Chapter 3: Detailed analysis of Lacosamide company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Lacosamide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Lacosamide in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Lacosamide Industry Trends Table 2. Lacosamide Industry Drivers Table 3. Lacosamide Industry Opportunities and Challenges Table 4. Lacosamide Industry Restraints Table 5. Global Lacosamide Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Lacosamide Revenue Share by Company (2021-2026) Table 7. Global Lacosamide Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Lacosamide Key Company Manufacturing Base & Headquarters Table 9. Global Lacosamide Company, Product Type & Application Table 10. Global Lacosamide Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Lacosamide by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Intravenous Table 15. Significant Companies of Oral tablets Table 16. Significant Companies of Oral solution Table 17. Global Lacosamide Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Lacosamide Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Lacosamide Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Lacosamide Sales Value Share by Type (2021-2026) Table 21. Global Lacosamide Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Adults Table 23. Significant Companies of Pediatric patients Table 24. Global Lacosamide Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Lacosamide Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Lacosamide Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Lacosamide Sales Value Share by Application (2021-2026) Table 28. Global Lacosamide Sales Value Share by Application (2027-2032) Table 29. Global Lacosamide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Lacosamide Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Lacosamide Sales Value Share by Region (2021-2026) Table 32. Global Lacosamide Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Lacosamide Sales Value Share by Region (2027-2032) Table 34. Global Lacosamide Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Lacosamide Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Lacosamide Sales Value Market Share by Country (2021-2026) Table 37. Global Lacosamide Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Lacosamide Sales Value Market Share by Country (2027-2032) Table 39. UCB Company Information Table 40. UCB Business Overview Table 41. UCB Lacosamide Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. UCB Lacosamide Product Portfolio Table 43. UCB Recent Development Table 44. Teva Company Information Table 45. Teva Business Overview Table 46. Teva Lacosamide Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Teva Lacosamide Product Portfolio Table 48. Teva Recent Development Table 49. Sun Pharma Company Information Table 50. Sun Pharma Business Overview Table 51. Sun Pharma Lacosamide Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Sun Pharma Lacosamide Product Portfolio Table 53. Sun Pharma Recent Development Table 54. Mylan Company Information Table 55. Mylan Business Overview Table 56. Mylan Lacosamide Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Mylan Lacosamide Product Portfolio Table 58. Mylan Recent Development Table 59. MSN Laboratories Company Information Table 60. MSN Laboratories Business Overview Table 61. MSN Laboratories Lacosamide Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. MSN Laboratories Lacosamide Product Portfolio Table 63. MSN Laboratories Recent Development Table 64. Glenmark Company Information Table 65. Glenmark Business Overview Table 66. Glenmark Lacosamide Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Glenmark Lacosamide Product Portfolio Table 68. Glenmark Recent Development Table 69. Aurobindo Pharma Company Information Table 70. Aurobindo Pharma Business Overview Table 71. Aurobindo Pharma Lacosamide Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Aurobindo Pharma Lacosamide Product Portfolio Table 73. Aurobindo Pharma Recent Development Table 74. Apotex Company Information Table 75. Apotex Business Overview Table 76. Apotex Lacosamide Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Apotex Lacosamide Product Portfolio Table 78. Apotex Recent Development Table 79. Amneal Pharmaceuticals Company Information Table 80. Amneal Pharmaceuticals Business Overview Table 81. Amneal Pharmaceuticals Lacosamide Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Amneal Pharmaceuticals Lacosamide Product Portfolio Table 83. Amneal Pharmaceuticals Recent Development Table 84. Alembic Pharma Company Information Table 85. Alembic Pharma Business Overview Table 86. Alembic Pharma Lacosamide Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Alembic Pharma Lacosamide Product Portfolio Table 88. Alembic Pharma Recent Development Table 89. Accord Healthcare Company Information Table 90. Accord Healthcare Business Overview Table 91. Accord Healthcare Lacosamide Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Accord Healthcare Lacosamide Product Portfolio Table 93. Accord Healthcare Recent Development Table 94. Research Programs/Design for This Report Table 95. Authors List of This Report Table 96. Secondary Sources Table 97. Primary Sources List of Figures Figure 1. Lacosamide Product Image Figure 2. Global Lacosamide Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lacosamide Market Size (2021-2032) & (US$ Million) Figure 4. Global Lacosamide Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Intravenous Image Figure 8. Oral tablets Image Figure 9. Oral solution Image Figure 10. Global Lacosamide Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Lacosamide Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Lacosamide Sales Value Share by Type (2021-2032) Figure 13. Adults Image Figure 14. Pediatric patients Image Figure 15. Global Lacosamide Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Lacosamide Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Lacosamide Sales Value Share by Application (2021-2032) Figure 18. Global Lacosamide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Lacosamide Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Lacosamide Sales Value (2021-2032) & (US$ Million) Figure 21. North America Lacosamide Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Lacosamide Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Lacosamide Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Lacosamide Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Lacosamide Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Lacosamide Sales Value (2021-2032) & (US$ Million) Figure 27. South America Lacosamide Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Lacosamide Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Lacosamide Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Lacosamide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Lacosamide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Lacosamide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Intravenous
  • Oral tablets
  • Oral solution
Applications
  • Adults
  • Pediatric patients
Companies covered
  • UCB
  • Teva
  • Sun Pharma
  • Mylan
  • MSN Laboratories
  • Glenmark
  • Aurobindo Pharma
  • Apotex
  • Amneal Pharmaceuticals
  • Alembic Pharma
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Lacosamide Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Lacosamide Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Lacosamide Market Dynamics
  1. 2.1 Lacosamide Industry Trends
  2. 2.2 Lacosamide Industry Drivers
  3. 2.3 Lacosamide Industry Opportunities and Challenges
  4. 2.4 Lacosamide Industry Restraints
3 Lacosamide Market by Company
  1. 3.1 Global Lacosamide Company Revenue Ranking in 2025
  2. 3.2 Global Lacosamide Revenue by Company (2021-2026)
  3. 3.3 Global Lacosamide Company Ranking (2024-2026)
  4. 3.4 Global Lacosamide Company Manufacturing Base and Headquarters
  5. 3.5 Global Lacosamide Company Product Type and Application
  6. 3.6 Global Lacosamide Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Lacosamide Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Lacosamide Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Lacosamide Market by Type
  1. 4.1 Lacosamide Type Introduction
  2. 4.1.1 Intravenous
  3. 4.1.2 Oral tablets
  4. 4.1.3 Oral solution
  5. 4.2 Global Lacosamide Sales Value by Type
  6. 4.2.1 Global Lacosamide Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Lacosamide Sales Value by Type (2021-2032)
  8. 4.2.3 Global Lacosamide Sales Value Share by Type (2021-2032)
5 Lacosamide Market by Application
  1. 5.1 Lacosamide Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Pediatric patients
  4. 5.2 Global Lacosamide Sales Value by Application
  5. 5.2.1 Global Lacosamide Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Lacosamide Sales Value by Application (2021-2032)
  7. 5.2.3 Global Lacosamide Sales Value Share by Application (2021-2032)
6 Lacosamide Regional Value Analysis
  1. 6.1 Global Lacosamide Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lacosamide Sales Value by Region (2021-2032)
  3. 6.2.1 Global Lacosamide Sales Value by Region: 2021-2026
  4. 6.2.2 Global Lacosamide Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Lacosamide Sales Value (2021-2032)
  7. 6.3.2 North America Lacosamide Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Lacosamide Sales Value (2021-2032)
  10. 6.4.2 Europe Lacosamide Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Lacosamide Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Lacosamide Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Lacosamide Sales Value (2021-2032)
  16. 6.6.2 South America Lacosamide Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Lacosamide Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Lacosamide Sales Value Share by Country, 2025 VS 2032
7 Lacosamide Country-level Value Analysis
  1. 7.1 Global Lacosamide Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Lacosamide Sales Value by Country (2021-2032)
  3. 7.2.1 Global Lacosamide Sales Value by Country (2021-2026)
  4. 7.2.2 Global Lacosamide Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Lacosamide Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Lacosamide Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Lacosamide Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Lacosamide Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Lacosamide Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Lacosamide Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Lacosamide Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Lacosamide Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Lacosamide Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Lacosamide Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Lacosamide Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Lacosamide Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Lacosamide Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Lacosamide Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Lacosamide Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Lacosamide Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Lacosamide Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Lacosamide Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Lacosamide Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Lacosamide Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Lacosamide Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Lacosamide Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Lacosamide Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Lacosamide Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Lacosamide Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Lacosamide Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Lacosamide Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Lacosamide Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Lacosamide Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Lacosamide Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Lacosamide Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Lacosamide Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Lacosamide Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Lacosamide Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Lacosamide Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Lacosamide Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Lacosamide Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Lacosamide Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Lacosamide Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Lacosamide Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Lacosamide Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Lacosamide Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Lacosamide Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Lacosamide Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Lacosamide Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Lacosamide Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Lacosamide Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Lacosamide Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Lacosamide Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Lacosamide Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Lacosamide Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Lacosamide Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Lacosamide Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Lacosamide Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Lacosamide Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Lacosamide Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Lacosamide Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Lacosamide Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Lacosamide Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Lacosamide Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Lacosamide Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Lacosamide Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Lacosamide Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Lacosamide Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Lacosamide Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Lacosamide Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Lacosamide Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Lacosamide Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Lacosamide Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Lacosamide Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Lacosamide Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Lacosamide Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Lacosamide Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Lacosamide Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Lacosamide Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Lacosamide Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Lacosamide Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Lacosamide Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Lacosamide Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Lacosamide Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Lacosamide Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Lacosamide Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Lacosamide Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Lacosamide Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 UCB
  2. 8.1.1 UCB Company Information
  3. 8.1.2 UCB Business Overview
  4. 8.1.3 UCB Lacosamide Revenue and Gross Margin (2021-2026)
  5. 8.1.4 UCB Lacosamide Product Portfolio
  6. 8.1.5 UCB Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Lacosamide Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Lacosamide Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sun Pharma
  14. 8.3.1 Sun Pharma Company Information
  15. 8.3.2 Sun Pharma Business Overview
  16. 8.3.3 Sun Pharma Lacosamide Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sun Pharma Lacosamide Product Portfolio
  18. 8.3.5 Sun Pharma Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Lacosamide Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Lacosamide Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 MSN Laboratories
  26. 8.5.1 MSN Laboratories Company Information
  27. 8.5.2 MSN Laboratories Business Overview
  28. 8.5.3 MSN Laboratories Lacosamide Revenue and Gross Margin (2021-2026)
  29. 8.5.4 MSN Laboratories Lacosamide Product Portfolio
  30. 8.5.5 MSN Laboratories Recent Developments
  31. 8.6 Glenmark
  32. 8.6.1 Glenmark Company Information
  33. 8.6.2 Glenmark Business Overview
  34. 8.6.3 Glenmark Lacosamide Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Glenmark Lacosamide Product Portfolio
  36. 8.6.5 Glenmark Recent Developments
  37. 8.7 Aurobindo Pharma
  38. 8.7.1 Aurobindo Pharma Company Information
  39. 8.7.2 Aurobindo Pharma Business Overview
  40. 8.7.3 Aurobindo Pharma Lacosamide Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Aurobindo Pharma Lacosamide Product Portfolio
  42. 8.7.5 Aurobindo Pharma Recent Developments
  43. 8.8 Apotex
  44. 8.8.1 Apotex Company Information
  45. 8.8.2 Apotex Business Overview
  46. 8.8.3 Apotex Lacosamide Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Apotex Lacosamide Product Portfolio
  48. 8.8.5 Apotex Recent Developments
  49. 8.9 Amneal Pharmaceuticals
  50. 8.9.1 Amneal Pharmaceuticals Company Information
  51. 8.9.2 Amneal Pharmaceuticals Business Overview
  52. 8.9.3 Amneal Pharmaceuticals Lacosamide Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Amneal Pharmaceuticals Lacosamide Product Portfolio
  54. 8.9.5 Amneal Pharmaceuticals Recent Developments
  55. 8.10 Alembic Pharma
  56. 8.10.1 Alembic Pharma Company Information
  57. 8.10.2 Alembic Pharma Business Overview
  58. 8.10.3 Alembic Pharma Lacosamide Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Alembic Pharma Lacosamide Product Portfolio
  60. 8.10.5 Alembic Pharma Recent Developments
  61. 8.11 Accord Healthcare
  62. 8.11.1 Accord Healthcare Company Information
  63. 8.11.2 Accord Healthcare Business Overview
  64. 8.11.3 Accord Healthcare Lacosamide Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Accord Healthcare Lacosamide Product Portfolio
  66. 8.11.5 Accord Healthcare Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst